PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
R&D reduction while TRAW shows 17.61% growth. Joel Greenblatt would examine competitive risk.
108.24%
G&A change of 108.24% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-3.86%
Operating expenses reduction while TRAW shows 11.35% growth. Joel Greenblatt would examine advantage.
-3.86%
Total costs reduction while TRAW shows 11.35% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-1.12%
D&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-1.49%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
3.86%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-73.89%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
12.77%
EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
13.49%
Diluted EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
16.41%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
17.29%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.